DDInter1378 DDInter1658
Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Paclitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Paclitaxel {u} (Compound) treats {v} (Disease) breast cancer
Paclitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Paclitaxel {u} (Compound) upregulates {v} (Gene) CDCA8
Paclitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Paclitaxel {u} (Compound) downregulates {v} (Gene) SCAND1
Paclitaxel {u} (Compound) causes {v} (Side Effect) Swelling face
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Paclitaxel (Compound) resembles Docetaxel (Compound)
Paclitaxel (Compound) treats breast cancer (Disease)
Paclitaxel (Compound) binds CYP3A5 (Gene)
Paclitaxel (Compound) upregulates CDCA8 (Gene)
Paclitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Paclitaxel (Compound) downregulates SCAND1 (Gene)
Paclitaxel (Compound) causes Swelling face (Side Effect)
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Delafloxacin